AlveoliX AG Revenue and Competitors
Estimated Revenue & Valuation
- AlveoliX AG's estimated annual revenue is currently $2.5M per year.
- AlveoliX AG's estimated revenue per employee is $155,000
Employee Data
- AlveoliX AG has 16 Employees.
- AlveoliX AG grew their employee count by -11% last year.
AlveoliX AG's People
Name | Title | Email/Phone |
---|
AlveoliX AG Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is AlveoliX AG?
Our Vision We aim at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs' responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing. Our Mission AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs.
keywords:N/AN/A
Total Funding
16
Number of Employees
$2.5M
Revenue (est)
-11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AlveoliX AG News
Alveolix AG Lung-on-Chip System zur Verbesserung der Arzneimittelentwicklung: Das Berner Start-up hat sich zum Ziel gesetzt,...
Additionally, we are proud to share in celebrating this achievement with fellow finalists, AlveoliX AG and Biospectal SA,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.4M | 16 | -30% | N/A |
#2 | $2.2M | 18 | 6% | N/A |
#3 | $3.7M | 19 | 12% | N/A |
#4 | N/A | 19 | -10% | N/A |
#5 | $1.7M | 24 | N/A | N/A |